BIO ANALYTICAL METHOD FOR QUANTITATIVE ESTIMATION, PHARMACOKINETIC AND BIOEQUIVALENCE STUDY OF NIZATIDINE NOVEL RAFT GASTRO RETENTIVE FORMULATION USING RP-HPLC
DOI:
https://doi.org/10.22159/ajpcr.2025v18i6.54742Keywords:
In vivo pharmacokinetic study, Nizatidine, Bio-analytical method, Bioavailability, Bioequivalence, In vitro in vivo correlationAbstract
Objective: This study presents for the development and validation of RP-HPLC method for the determination of nizatidine in rabbit plasma.
Methods: The method was used to perform a pharmacokinetics and bio-equity study to compare a raft gastro-retentive formulation of nizatidine with a marketed formulation. Nizatidine is a competitive H2 receptor antagonist that prescribed for the treatment of different disorders connected with gastric acid production, mainly for nocturnal acid secretion. Twelve New Zealand white rabbits were divided into two groups: one of them receive the new raft formulation that is made up from novel ingredients and the second one receive the marketed raft formulation.
Results: The results indicated that the novel raft formulation significantly enhanced the bioavailability of nizatidine, with higher Cmax (230.28±0.61 ng/ml) and AUC0-∞ (1826.17±2.38 ng•h/ml) compared to the marketed formulation (Cmax: 210.Mean Cmax values for esomeprazole were 8±4.5 ng/ml, and Cmax for the metabolite were 6.5±1.9 ng/ml AUC0-∞ was 619.1±21,14 ng•h/ml.
Conclusion: Also, the physical characterization demonstrated that, for the raft formulation, the mean resident time (MRT) was higher (7.22 ± 0.014 h) than that of the marketed product (3.17 ± 0.07 h) and suggested a sustained release product. A strong in vitro-in vivo correlation (IVIVC) R² = 0.9162 was confirmed to the predictability of the raft formulations performance
Downloads
References
Sable VU, Gupta MK, Jain NK, Singh G. Design, development and evaluation of oral sustained release in-situ floating gel as a carrier for stomach specific delivery of antiulcer drug. Int J Pharmacol Res. 2020;12(3):132.
Jeon HK, Kim GH. Can nocturnal acid-breakthrough be reduced by long-acting proton pump inhibitors? J Neurogastroenterol Motil. 2017;23(2):145-8. doi: 10.5056/jnm17037, PMID 28372039
Chiverton SG, Burget DW, Hunt RH. Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity. Gut. 1989;30(5):594-9. doi: 10.1136/gut.30.5.594, PMID 2567265
Samala ML, Janga RB. Design, statistical optimization of nizatidine floating tablets using natural polymer. Futur J Pharm Sci. 2021;7(1):2. doi: 10.1186/s43094-020-00140-z
Sagar S, Srinivas L. Development and evaluation of raft forming gastroretentive floating drug delivery system of nizatidine by design of experiment. Int J Appl Pharm. 2022;14(2):242-51.
Bhosale MM, Shirote PJ. Development and optimization of raft-forming formulation of H2 blockers. Asian J Pharm Clin Res. 2024;17(4):66-70.
Price AH, Brogden RN. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs. 1988;36(5):521-39. doi: 10.2165/00003495-198836050-00002, PMID 2905640
Rao PV, Kumar MR, Prasad V, Rao DD. Stability-indicating LC method for the estimation of nizatidine impurities in nizatidine oral solution. J Liq Chromatogr Relat Technol. 2014;37(7):1065-78. doi: 10.1080/10826076.2013.765461
Akmeşe B, Altun Y, Şanlı S, Şanlı N. RP-LC determination of dissociation constants and quantitative estimation of antiulcer drugs, famotidine, nizatidine and ranitidine in their dosage forms. Hacet J Biol Chem. 2015;43(3):159-66.
Ho C, Huang HM, Hsu SY, Shaw CY, Chang BL. Simultaneous high-performance liquid chromatographic analysis for famotidine, ranitidine HCl, cimetidine, and nizatidine in commercial products. Drug Dev Ind Pharm. 1999;25(3):379-85. doi: 10.1081/ddc-100102186, PMID 10071834
Belal TS, Abdel-Hay MH, Sabry SM, Mahgoub AA. HPLC-DAD stability indicating determination of nizatidine in bulk and capsules dosage form. Bull Fac Pharm Cairo Univ. 2013;51(2):185-91. doi:10.1016/j.bfopcu.2013.05.001
Jang WS, Song IC, Chang GS. Interpretation of animal dose and human equivalent dose for drug development. J Korean Orient Med. 2010;31(3):1-7.
Nair AB, Jacob S. A Simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31. doi: 10.4103/0976-0105.177703, PMID 27057123
Sabry SA, Hasan AA, Abdallah MH. Gastroretentive nizatidine loading microballoons for treatment of peptic ulcer. Int J Pharm Pharm Sci. 2015;7(10):220-5.
Seema SR, Navyashree GA, Manyatha D, Sunil S. Analytical techniques for nizatidine: A review. Sep Sci Plus. 2019;9:329-42.
Birajdar AA, Deshmukh MT, Shete RV. A Review on Gastro-Retentive Floating Microspheres. J. Drug Delivery Ther 2021;11(1-S):131-8.
Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics. 2nd ed. Delhi: VallabhPrakashan; 2009. p. 399-401.
Nandy BC, Roy S, Mazumder M, Meena KC, Makhija M, Jain S, et al. In vitro in vivo correlation: Application in pharmaceutical innovation. Int J Pharm Sci Drug Res. 2011;3(5):550-64.
Davanço MG, Campos DR, Carvalho PO. In vitro-in vivo correlation in the development of oral drug formulation: A screenshot of the last two decades. Int J Pharm. 2020;850:1-17.
Dessy N, Siahaan R, Bangun H, Sumaiyah S. In vitro and in vivo evaluation of floating gastroretentive drug delivery system of cimetidine using hard alginate capsules. Asian J Pharm Clin Res. 2018;11(6):162-8. doi: 10.22159/ajpcr.2018.v11i6.24731
Published
How to Cite
Issue
Section
Copyright (c) 2025 shanti sagar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
